Abstract
To investigate the budgetary impact from the introduction of a new combination of ezetimibe and atorvastatin (EZE/ATOR_CH [Cholzet]), as adjunct to diet for treatment in primary hypercholesterolaemia in patients who are not appropriately controlled with a statin alone or in whom a statin is considered inappropriate or is not tolerated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
